
Overview
Dr. Girard attended the University of Michigan College of Engineering as an undergraduate and worked as a biochemical engineer manufacturing vaccines for clinical trials for five years before attending medical school at the University of Illinois. She completed her residency in Internal Medicine at Beth Israel Deaconess Hospital, a Harvard affiliated program in Boston, MA and completed her fellowship training in Hematology/Oncology at the University of Michigan in Ann Arbor MI.
Dr. Girard is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Pulmonary Embolism, Antiphospholipid Syndrome, Platelet Storage Pool Deficiency, and Bernard-Soulier Syndrome.
Dr. Girard is board certified in Hematology, Internal Medicine, and Medical Oncology. She is actively involved in clinical research, co-authoring 6 peer reviewed articles. Dr. Girard is currently accepting new patients.
Specialties
Licenses
Board Certifications
Fellowships
Hospital Affiliations
Languages Spoken
Gender
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- EPO
- HMO
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- OTHER MANAGED MEDICAID
- HMO
- OTHER MEDICAID
- STATE MEDICAID
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- HMO
- POS
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- OTHER COMMERCIAL
- OTHER MEDICARE PART D
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER COMMERCIAL
- OTHER COMMERCIAL
- EPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MEDICARE MAPD
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- MEDICARE DISCOUNT CARD
- MEDICARE PDP
- OTHER MEDICARE
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
1540 E Hospital Dr, Floor 9, Ann Arbor, MI 48109
Additional Areas of Focus
Dr. Girard has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Rogel Cancer Center
Rashmi Chugh is a Hematologist and an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Chugh is highly rated in 32 conditions, according to our data. Her clinical expertise encompasses Adult Soft Tissue Sarcoma, Epithelioid Sarcoma, Desmoid Tumor, and Ewing Sarcoma. Dr. Chugh is currently accepting new patients.
Rogel Cancer Center
Dr. Francis Worden received his medical degree from the Indiana University School of Medicine in 1993. Prior to attending medical school, he worked as a registered pharmacist at a large community hospital in Indianapolis. In 1997, Dr. Worden completed a combined residency in internal medicine and pediatrics at the Detroit Medical Center and finished a medical oncology/hematology fellowship at the University of Michigan. In July 2000, Dr. Worden joined the faculty at the University of Michigan Rogel Cancer Center, where he is currently working as a clinical investigator with both the multidisciplinary head and neck oncology team and the multidisciplinary lung cancer team. Dr. Worden's research interests include organ preservation in head and neck cancer and endocrine oncology. He is the Nancy Wigginton Oncology Research Professor of Thyroid Cancer. Avid competitive swimmer ; cyclist and runner. Dr. Worden is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Laryngeal Cancer, Throat Cancer, Thyroid Cancer, and Head and Neck Squamous Cell Carcinoma (HNSCC). Dr. Worden is board certified in Medical Oncology. Dr. Worden is currently accepting new patients.
Rogel Cancer Center
Scott Schuetze is an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Schuetze is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Liposarcoma, Adult Soft Tissue Sarcoma, Angiosarcoma, and Myxoid Liposarcoma. Dr. Schuetze is currently accepting new patients.
Rogel Cancer Center
Dr. Vaishampayan is the Director of the Phase I program at the Rogel Cancer Center, University of Michigan, Ann Arbor MI. Dr. Vaishampayan is a Professor of Internal Medicine and her research is primarily in translational drug development and early phase clinical trials in cancer with a focus on genitourinary malignancies. She has initiated, obtained funding for, and conducted and published many investigator initiated trials with embedded biomarkers and established multidisciplinary collaboration. She has served as site PI of the UO-1 Early Therapeutics Research Grant at Wayne State University. She was also the chair of the solid tumor division of oncology at WSU. She has completed formal leadership traning course and is Fellow of the Advisory Board (FAB). She is the appointed chair of the Advanced Renal committee of SWOG and a member of the Renal task force of the NCI. She is a board member of the Michigan Society of Hematology/Oncology (MSHO) and organizes annual board review course. Additionally, she has served as track leader for the ASCO education committee GU non prostate (Renal and bladder cancer) track. Dr. Vaishampayan attended Wayne State University for her residency and fellowship completion and attended medical school at Byramjee Jeejeebhoy in Pune, India and completed a higher secondary certificate in the field of science at Fergusson College in Pune, India.In her free time, Dr. Vaishampayan enjoys reading, dance, music and travel. Travel, reading (mysteries preferred), follows football. Dr. Vaishampayan is highly rated in 32 conditions, according to our data. Her clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostate Cancer, Nephrectomy, and Orchiectomy. Dr. Vaishampayan is board certified in Medical Oncology. Dr. Vaishampayan is currently accepting new patients.
Rogel Cancer Center
The T-cell lymphomas are a heterogeneous and poorly understood group of non-Hodgkin’s lymphomas. The most common T-cell lymphoma in the United States includes a heterogeneous mix of lymphomas that lack distinguishing characteristics and, until recently, remained clinically and molecularly “unspecified”. Improved understanding of T-cell lymphoma pathogenesis and the development of novel therapeutic strategies will be needed to address this challenge and improve outcomes for patients afflicted with these aggressive lymphomas. My group made the landmark discovery that the most common T-cell lymphoma in North America is comprised of two molecularly and clinically distinct subsets. This finding has significant implications for the classification and treatment of these lymphomas. We have also demonstrated that malignant T cells remain dependent upon antigen-presenting cells within the tumor microenvironment and are developing novel therapeutic strategies targeting these cells. Many fundamental questions, including the “cell of origin”, the role of antigen-, costimulatory-, and cytokine-receptor signaling, and the contribution of myeloid-derived antigen-presenting cells in disease pathogenesis remain obscure. My laboratory uses complementary mouse models and primary T-cell lymphoma specimens (in ex vivo and patient-derived xenograft studies) to address these fundamental and clinically relevant questions. We are poised to clinically translate our laboratory-based findings into novel therapeutic strategies that we hope will improve outcomes for patients afflicted with these aggressive lymphomas. I enjoy working with a multidisciplinary team of enthusiastic collaborators who share this common goal. Dr. Wilcox is highly rated in 24 conditions, according to our data. His clinical expertise encompasses T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Peripheral T-Cell Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Wilcox is board certified in Hematology, Internal Medicine, and Medical Oncology. Dr. Wilcox is currently accepting new patients.
University Of Michigan Rogel Cancer Center
Dr. Kalemkerian completed his medical education and training at Northwestern University and Johns Hopkins Oncology Center. From 1993-1999, he was a physician-scientist at Wayne State University/Karmanos Cancer Institute in Detroit. Since 1999, he has been on faculty in the Division of Hematology/Oncology at the University of Michigan, where he currently serves as the Associate Division Chief for Faculty Development and Education and the Associate Director of the Hem/Onc Fellowship Program. In addition to his work at UM, Dr. Kalemkerian has served on and led numerous grant review sections, editorial boards, and committees of national and international professional societies. He is a former chair of the NCCN Small Cell Lung Cancer Guideline Panel and the ASCO Scientific Program Committee’s Metastatic NSCLC and Professional Development and Education Tracks. Dr. Kalemkerian’s clinical interest is the care of people with lung cancer, thymic tumors, and mesothelioma, and his academic research interest is clinical and translational trials for thoracic cancers. His honors include the receipt of the American Society of Clinical Oncology’s (ASCO) Excellence in Teaching Award, the University of Michigan Outstanding Clinician Award, and Fellow of ASCO recognition. He has given over 230 invited lectures, authored more than 200 research articles, reviews, commentaries and book chapters, and edited two books on lung cancer. Dr. Kalemkerian is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma. Dr. Kalemkerian is board certified in Internal Medicine and Medical Oncology. Dr. Kalemkerian is currently accepting new patients.
Frequently Asked Questions about Dr. Jennifer E. Girard
Is Dr. Jennifer E. Girard a top-rated expert for Pulmonary Embolism?
MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jennifer E. Girard is classified as an Distinguished expert for Pulmonary Embolism, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
What conditions does Dr. Jennifer E. Girard specialize in?
While Dr. Jennifer E. Girard is a Hematology, they have specific expertise in Pulmonary Embolism, Antiphospholipid Syndrome, and Platelet Storage Pool Deficiency. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.
Does Dr. Jennifer E. Girard participate in research or clinical trials?
Yes. Dr. Jennifer E. Girard has published 6 articles and abstracts on conditions like Pulmonary Embolism. You can view a list of Dr. Jennifer E. Girard's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Does Dr. Jennifer E. Girard accept my insurance?
Dr. Jennifer E. Girard accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly to verify that your specific plan is currently accepted before your visit.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Antiphospholipid SyndromeDr. Girard isDistinguished. Learn about Antiphospholipid Syndrome.
- Pulmonary EmbolismDr. Girard isDistinguished. Learn about Pulmonary Embolism.
- Advanced
- Acute Hepatic Porphyria (AHP)Dr. Girard isAdvanced. Learn about Acute Hepatic Porphyria (AHP).
- Adult Immune ThrombocytopeniaDr. Girard isAdvanced. Learn about Adult Immune Thrombocytopenia.
- Arterial EmbolismDr. Girard isAdvanced. Learn about Arterial Embolism.
- Bernard-Soulier SyndromeDr. Girard isAdvanced. Learn about Bernard-Soulier Syndrome.
- Deep Vein ThrombosisDr. Girard isAdvanced. Learn about Deep Vein Thrombosis.
- Glanzmann ThrombastheniaDr. Girard isAdvanced. Learn about Glanzmann Thrombasthenia.
- Gray Platelet SyndromeDr. Girard isAdvanced. Learn about Gray Platelet Syndrome.
- Hemangioma Thrombocytopenia Syndrome
- Hereditary Hemorrhagic Telangiectasia
- Immune Thrombocytopenic Purpura (ITP)
- Platelet Storage Pool DeficiencyDr. Girard isAdvanced. Learn about Platelet Storage Pool Deficiency.
- Saddle Pulmonary EmbolismDr. Girard isAdvanced. Learn about Saddle Pulmonary Embolism.
- Shwartzman PhenomenonDr. Girard isAdvanced. Learn about Shwartzman Phenomenon.
- ThrombocytopeniaDr. Girard isAdvanced. Learn about Thrombocytopenia.
- Venous Thromboembolism (VTE)Dr. Girard isAdvanced. Learn about Venous Thromboembolism (VTE).
- Experienced
- Acquired HemophiliaDr. Girard isExperienced. Learn about Acquired Hemophilia.
- Acute Intermittent PorphyriaDr. Girard isExperienced. Learn about Acute Intermittent Porphyria.
- AgranulocytosisDr. Girard isExperienced. Learn about Agranulocytosis.
- AnemiaDr. Girard isExperienced. Learn about Anemia.
- Arteriovenous MalformationDr. Girard isExperienced. Learn about Arteriovenous Malformation.
- Ataxia-Pancytopenia SyndromeDr. Girard isExperienced. Learn about Ataxia-Pancytopenia Syndrome.
- Beta ThalassemiaDr. Girard isExperienced. Learn about Beta Thalassemia.
- Blood ClotsDr. Girard isExperienced. Learn about Blood Clots.
- Budd-Chiari SyndromeDr. Girard isExperienced. Learn about Budd-Chiari Syndrome.
- Chronic Familial NeutropeniaDr. Girard isExperienced. Learn about Chronic Familial Neutropenia.
- Congenital Hemolytic AnemiaDr. Girard isExperienced. Learn about Congenital Hemolytic Anemia.
- D-Minus Hemolytic Uremic SyndromeDr. Girard isExperienced. Learn about D-Minus Hemolytic Uremic Syndrome.
- Essential ThrombocythemiaDr. Girard isExperienced. Learn about Essential Thrombocythemia.
- Factor 11 DeficiencyDr. Girard isExperienced. Learn about Factor 11 Deficiency.
- Fanconi AnemiaDr. Girard isExperienced. Learn about Fanconi Anemia.
- Febrile NeutropeniaDr. Girard isExperienced. Learn about Febrile Neutropenia.
- Follicular LymphomaDr. Girard isExperienced. Learn about Follicular Lymphoma.
- Gallbladder DiseaseDr. Girard isExperienced. Learn about Gallbladder Disease.
- Hemolytic AnemiaDr. Girard isExperienced. Learn about Hemolytic Anemia.
- Hemolytic CrisisDr. Girard isExperienced. Learn about Hemolytic Crisis.
- Hemophagocytic LymphohistiocytosisDr. Girard isExperienced. Learn about Hemophagocytic Lymphohistiocytosis.
- Hemophilia ADr. Girard isExperienced. Learn about Hemophilia A.
- Hemophilia BDr. Girard isExperienced. Learn about Hemophilia B.
- Hemophilic ArthropathyDr. Girard isExperienced. Learn about Hemophilic Arthropathy.
- HemosiderosisDr. Girard isExperienced. Learn about Hemosiderosis.
- Hereditary SpherocytosisDr. Girard isExperienced. Learn about Hereditary Spherocytosis.
- Heyde SyndromeDr. Girard isExperienced. Learn about Heyde Syndrome.
- Idiopathic NeutropeniaDr. Girard isExperienced. Learn about Idiopathic Neutropenia.
- Idiopathic Pulmonary HemosiderosisDr. Girard isExperienced. Learn about Idiopathic Pulmonary Hemosiderosis.
- Langerhans Cell HistiocytosisDr. Girard isExperienced. Learn about Langerhans Cell Histiocytosis.
- LeukocytosisDr. Girard isExperienced. Learn about Leukocytosis.
- Lymphofollicular HyperplasiaDr. Girard isExperienced. Learn about Lymphofollicular Hyperplasia.
- Mantle Cell Lymphoma (MCL)Dr. Girard isExperienced. Learn about Mantle Cell Lymphoma (MCL).
- Mast Cell Activation Syndrome (MCAS)Dr. Girard isExperienced. Learn about Mast Cell Activation Syndrome (MCAS).
- May Thurner SyndromeDr. Girard isExperienced. Learn about May Thurner Syndrome.
- Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Myelodysplastic Syndrome (MDS)Dr. Girard isExperienced. Learn about Myelodysplastic Syndrome (MDS).
- MyelofibrosisDr. Girard isExperienced. Learn about Myelofibrosis.
- Non-Hodgkin LymphomaDr. Girard isExperienced. Learn about Non-Hodgkin Lymphoma.
- PorphyriaDr. Girard isExperienced. Learn about Porphyria.
- Primary Immunodeficiency (PID)Dr. Girard isExperienced. Learn about Primary Immunodeficiency (PID).
- Pure Red Cell AplasiaDr. Girard isExperienced. Learn about Pure Red Cell Aplasia.
- Schnitzler SyndromeDr. Girard isExperienced. Learn about Schnitzler Syndrome.
- Shwachman-Diamond SyndromeDr. Girard isExperienced. Learn about Shwachman-Diamond Syndrome.
- Sickle Cell DiseaseDr. Girard isExperienced. Learn about Sickle Cell Disease.
- SplenomegalyDr. Girard isExperienced. Learn about Splenomegaly.
- ThalassemiaDr. Girard isExperienced. Learn about Thalassemia.
- Virus Associated Hemophagocytic Syndrome
- Von Willebrand Disease (VWD)Dr. Girard isExperienced. Learn about Von Willebrand Disease (VWD).





